PYC Therapeutics Ltd (ASX: PYC) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


PYC Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $391.95 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 3.73 billion
Earnings per share -0.007
Dividend per share N/A
Year To Date Return 52.17%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • PYC Therapeutics Ltd (ASX: PYC)
    Latest News

    A medical researcher works on a bichip, indicating share price movement in ASX tech companies
    Share Market News

    Why is the PYC Therapeutics share price up 170% in a year?

    The PYC Therapeutics share price has risen 170% this year and 13% this month, following promising results in the development…

    Read more »

    row of piggy banks with large one receiving injection representing rising Immutep share price
    Share Market News

    Why the PYC Therapeutics (ASX:PYC) share price is up 11% today

    The PYC Therapeutics share price is higher today after the company announced that it has added another drug to its…

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Share Market News

    Why the PYC Therapeutics (ASX:PYC) share price is up 9% today

    The PYC Therapeutics share price is up 9% today following a promising ASX announcement on the effectiveness of its lead…

    Read more »

    a woman
    ⏸️ Investing

    Why Phylogica Limited soared 80% today

    Phylogica Limited (ASX:PYC) reports some excellent news

    Read more »

    PYC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About PYC Therapeutics Ltd

    PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principalbusiness activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

    PYC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    08 Dec 2023 $0.11 $0.00 0.00% 897,757 $0.11 $0.11 $0.10
    07 Dec 2023 $0.11 $0.00 0.00% 3,467,191 $0.10 $0.12 $0.10
    06 Dec 2023 $0.10 $0.00 0.00% 1,788,575 $0.10 $0.11 $0.10
    05 Dec 2023 $0.10 $0.00 0.00% 2,409,590 $0.10 $0.10 $0.09
    04 Dec 2023 $0.10 $-0.01 -9.09% 5,334,026 $0.11 $0.12 $0.10
    01 Dec 2023 $0.11 $0.02 21.28% 10,496,918 $0.10 $0.11 $0.09
    30 Nov 2023 $0.09 $0.01 11.63% 9,134,647 $0.09 $0.11 $0.09
    29 Nov 2023 $0.09 $0.00 0.00% 4,114,717 $0.08 $0.09 $0.08
    28 Nov 2023 $0.08 $0.00 0.00% 4,289,098 $0.08 $0.09 $0.08
    27 Nov 2023 $0.08 $0.00 0.00% 1,929,109 $0.08 $0.08 $0.08
    24 Nov 2023 $0.08 $0.00 0.00% 2,566,145 $0.08 $0.08 $0.08
    23 Nov 2023 $0.08 $0.00 0.00% 1,483,243 $0.08 $0.08 $0.08
    22 Nov 2023 $0.08 $0.00 0.00% 1,029,870 $0.08 $0.08 $0.07
    21 Nov 2023 $0.08 $0.00 0.00% 3,075,440 $0.08 $0.08 $0.08
    20 Nov 2023 $0.08 $0.00 0.00% 1,816,521 $0.08 $0.08 $0.07
    17 Nov 2023 $0.07 $0.00 0.00% 2,458,909 $0.07 $0.07 $0.07
    16 Nov 2023 $0.07 $0.00 0.00% 2,365,924 $0.08 $0.08 $0.07
    15 Nov 2023 $0.07 $0.00 0.00% 1,916,069 $0.07 $0.07 $0.07
    14 Nov 2023 $0.07 $0.00 0.00% 1,385,631 $0.07 $0.07 $0.07
    13 Nov 2023 $0.07 $0.00 0.00% 5,744,025 $0.07 $0.08 $0.07
    10 Nov 2023 $0.07 $0.01 16.95% 3,820,471 $0.06 $0.07 $0.06
    09 Nov 2023 $0.06 $0.00 0.00% 2,367,775 $0.06 $0.06 $0.06

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    14 Jul 2023 Alan Tribe Issued 254,545,459 $14,000,000
    10 Jul 2023 Rohan Hockings Issued 18,181,818 $999,999
    10 Jul 2023 Rohan Hockings Transfer 10,000,000 $620,000
    Off-market transfer.
    29 Jun 2023 Alan Tribe Buy 82,610 $4,378
    On-market trade.
    26 Jun 2023 Alan Tribe Buy 1,590,767 $85,106
    On-market trade. As per announcement on 28-06-2023

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Alan William Tribe Non-Executive ChairmanNon-Executive Director Apr 2018
    Mr Tribe has a background in the accounting profession both in the UK and Australia. Moving into industry he became the Managing Director of a group of companies with interests in natural resources in Australia and overseas. The group also included a technology Group which grew through both successful product development and acquisitions. He was closely involved in establishing subsidiary operations in the USA, UK and Singapore to access markets worldwide. Most recently he was the catalyst for the development of large retail operations in Western and South Australia. Mr Tribe will contribute his experience in successfully commercialising technology internationally.
    Dr Rohan Hockings Executive DirectorChief Executive Officer Aug 2016
    Dr Hockings spent four years with McKinsey & Company and a further two years in the Private Equity industry before joining PYC Therapeutics. He brings an affinity for conceptual thinking to PYC Therapeutics along with an understanding of the company's technology and its commercialisation path. Dr Hockings is a founding principal of a private equity fund active in the acquisition of health care assets within Australia. His previous roles include strategy and operational advisory positions with a global management consulting firm, equity capital markets experience as a solicitor with a national law firm and a number of appointments as a medical practitioner. Dr Hockings has a special interest in both venture capital and private equity within the healthcare industry. Dr Hockings holds double degrees in medicine and law. He has worked across both disciplines following an internship at Sir Charles Gairdner Hospital and admission to practice in the Supreme Court of Victoria respectively.
    Dr Michael Rosenblatt Non-Executive Director Mar 2021
    Dr Rosenblatt is currently a Senior Partner of Flagship Pioneering. Dr Rosenblatt joined Flagship from Merck, where he served as Executive Vice President and Chief Medical Officer from 2009 to 2016. During an earlier period at Merck, he led drug discovery efforts in ophthalmology, molecular biology, bone biology, virology, cancer research, gastroenterology, lipid metabolism and cardiovascular research. He has held appointments as Dean of Tufts University School of Medicine; Robert H. Ebert Professor of Molecular Medicine and George R. Minot Professor of Medicine, both at Harvard Medical School; President, Harvard Faculty Dean and Senior Vice President for Academic Programs of Beth Israel Deaconess Medical Center; and Director of the Harvard-MIT Division of Health Sciences and Technology. Dr Rosenblatt has served as a founding scientist, scientific advisory board member or director of more than 12 biopharmaceutical companies. He completed internship, residency and endocrinology training at the Massachusetts General Hospital.
    Mr Jason Haddock Non-Executive Director Mar 2021
    Mr Haddock has more than 20 years of financial and operational experience in the biopharmaceutical industry and currently serves as a Board Director of Codiak Biosciences, a biotech company developing precision exosome therapeutics. He served as CFO at Array BioPharma, Inc., where he was instrumental in the execution of an oncology-focused research, development and commercialization strategy that culminated in the successful launch of two new drugs and the company ultimately being acquired by Pfizer. Prior, he worked at Bristol-Myers Squibb in a variety of finance, strategic, commercial and business development capacities, including CFO and COO roles for business units in Asia Pacific, Europe and the United States. Mr. Haddock has also served as CFO for ArcherDX as the company was acquired by Invitae to create a global leader in comprehensive cancer genetics and precision oncology.
    Mr Kevin R Hart Chief Financial OfficerCompany Secretary Jul 2017
    Mr Andrew Taylor Company Secretary Jun 2023
    Kevin R Hart Chief Financial OfficerCompany Secretary
    Andrew Taylor Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    No information of Shareholder 0 0.00%